A human-reviewed diagnostic and actionable roadmap for Korean Bio, Healthcare, FemTech and selected innovation companies preparing for the U.S. market — followed, when a company is ready, by managed institutional preparation and execution.
Company-specific work begins with the $899 U.S. Entry Diagnostic & Roadmap.
Start the $899 Entry Diagnostic View Sample Deliverables →More than an introduction. A managed market-entry process.
The introduction is not the product. The preparation and execution around it are.
KCED Gateway is not a general-purpose export platform. In these sectors, generic market research is not what companies are missing — sequence and preparation are.
Fertility, postpartum, menopause, women's diagnostics and devices.
Novel drugs, biologics, preclinical through clinical stage.
Hospital- and clinic-facing services and care platforms.
Device companies needing U.S. regulatory and market-entry preparation.
In-vitro diagnostics, at-home testing, laboratory services.
SaMD, clinical decision support, patient-data-driven services.
Four stages, one managed process. A company enters where it is — and only continues when it is ready.
Should this company enter the U.S. market now, and what must happen first?
Is this company ready to be placed in front of serious U.S. institutions?
KCED begins managed institutional execution in the U.S.
If active opportunities remain, KCED may continue execution month-to-month.
Every company begins with the Diagnostic. What follows depends on what the Diagnostic finds — not on a fixed upsell.
A standalone professional product. You receive a useful, evidence-based result even if you purchase nothing afterward.
A fixed-duration, fixed-scope engagement that prepares the company before KCED spends significant institutional relationship capital — ending in a clear Activation Decision.
A three-month professional engagement in which KCED acts as your temporary U.S. / New Jersey market-entry execution office — strategy, institutional relations, communications, coordination and follow-through.
A separate, limited 2026 program for four selected FemTech companies: two weeks of company and institutional preparation plus three days of tailored New Jersey market access (Oct 27–29). Includes its own preparation — selected companies do not also purchase the $6,500 Sprint.
The $899 Diagnostic fee may be credited toward a subsequent engagement contracted within the approved validity window, confirmed by a KCED administrator. KCED supports preparation and outreach toward institutions that fit, but does not guarantee introductions, meetings, investment, grants, pilots or partnership outcomes.
Not an application fee, not a free consultation, not a sales call disguised as an assessment. It can also conclude that a company should not begin U.S. institutional outreach yet.
Proceed toward the 90-Day Activation Program.
Prepare positioning, materials and institutional narrative first.
A regulatory, legal, clinical, tax or investment question must be resolved with qualified experts.
Pause. Approaching institutions now would spend credibility that is hard to recover.
Prepare the company before KCED spends relationship capital. A fixed-duration, fixed-scope engagement — not generic consulting, and not a discounted Activation.
Proceed to the 90-Day U.S. Market Activation Program.
Resolve an FDA/regulatory, legal, clinical, reimbursement, tax, immigration or investment-readiness issue before activation.
KCED hands over the completed preparation work. No continuing engagement required.
Pause U.S. institutional activation. No pressure to continue.
90 days of managed U.S. market-entry execution combining strategy, institutional relations, communications, coordination and follow-through. You are purchasing managed execution capacity — not random introductions or raw hours.
We review before we reach out. A person reads the company's actual materials first.
We prepare the company before using institutional relationships.
We define the purpose of each engagement. Every target has a reason to participate.
We prepare both sides. Materials, context and objectives are ready in advance.
We document next actions. Meetings end in decisions, requests or a clear reason not to proceed.
We protect relationship quality.
“KCED identifies and approaches relevant institutions based on each company's readiness, technology and objective. KCED does not distribute its institutional network as a contact list — relationships are activated selectively when there is a credible reason for engagement.”
KCED does not issue automated readiness scores. A person reads the company's actual materials from the perspective of the U.S. counterpart who will receive them, and every finding is recorded with its reviewer, approval date and evidence.
Sylvia Kim's 26+ years across New Jersey government, business, healthcare and community life form the institutional relationship infrastructure behind KCED Gateway. She directly oversees KCED Gateway reviews and activation decisions.
This accumulated New Jersey relationship infrastructure now supports KCED Gateway's institutional-access and market-entry work — not as a personal consultancy, but as the operating basis for how KCED reaches and prepares institutions.
The examples below are sample formats, not client cases. The Diagnostic's documents are yours whether or not you continue.
What to clarify, what to rebuild and what to prepare before entering the U.S. — each with the reasoning behind it.
View sample format →The three things that block everything else — why these three, and what is deliberately deferred.
View sample format →What, by whom, by when — with a definition of done for every item.
View sample format →No. It is a standalone professional Diagnostic & Roadmap. The documents are yours whether or not you continue to another product.
No. The Diagnostic is a professional evaluation. FemTech selection is a separate, competitive process for the 2026 cohort of four.
No. A strong, ready company may go straight from the Diagnostic to Activation. The Sprint is for companies whose positioning, materials, regulatory story or institutional targeting need preparation first.
Positioning, materials, readiness mapping, institutional strategy and a 30/60/90 roadmap — ending in a clear Activation Decision at approximately Day 30.
Yes, subject to KCED qualification, if the Diagnostic finds the company ready. It is not recommended if materials fall short of U.S. expectations.
You receive an Activation Decision: ready to activate; a specialist issue to resolve first; ready to execute internally with KCED's handed-over work; or not ready.
Because it includes roughly two weeks of company and institutional preparation before the three-day New Jersey program — not just event days. See details →
No. KCED prepares and coordinates matched institutional engagement based on relevance, interest and availability.
If meaningful opportunities remain, KCED may continue execution month-to-month (from $5,000/month, subject to scope and capacity).
No. KCED provides Legal & Regulatory Coordination — identifying issues and coordinating with qualified outside professionals. It does not provide legal, regulatory, medical, tax or investment advice.
The first step for every company. A standalone professional deliverable that stands on its own.
Start the $899 Entry Diagnostic